Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Differences in Early Tacrolimus Exposure in Kidney Transplant Recipients With and Without CYP3A5 Genotype-Guided Tacrolimus Dosing.

Clinical and translational science - 1 Sept 2026

Pasternak Amy L, Schwartz Jenna, Vanderwerff Brett, Zöllner Sebastian, Haakinson Danielle J, Doshi Mona, Park Jeong M

Abstract excerpt

CYP3A5 genotype is a known predictor of tacrolimus dose requirements. This single-center retrospective study evaluated the impact of CYP3A5 genotype-guided dosing, implemented at our institution in 10/2023, on early tacrolimus exposure. Patients were included if they were adult kidney transplant recipients between 7/2014 and 10/2024; patients in the weight-based cohort had research CYP3A5 genotypes in the...

Read the complete abstract on PubMed

Topics

Humans
Tacrolimus
Cytochrome P-450 CYP3A
Kidney Transplantation
Female
Male

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Middle Aged

Retrospective Studies

Adult

Immunosuppressive Agents

Graft Rejection

Genotype

Pharmacogenomic Variants

Pharmacogenomic Testing

Source

Open in PubMed Open full text

Identifiers

PMID: 42748365
DOI: 10.1111/cts.70726
PMCID: PMC13581269

Genes

CYP3A5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 24 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Differences in Early Tacrolimus Exposure in Kidney Transplant Recipients With and Without CYP3A5 Genotype-Guided Tacrolimus Dosing.PMID 42748365Read ↗

Cohort Study to Determine the Impact of CYP3A5 Genotype on Tacrolimus Dosing Requirements and Trough Concentrations in Heart Transplant Recipients.Semantic proximity Read ↗

Clinical Impact of the Adaptation of Initial Tacrolimus Dosing to the CYP3A5 Genotype After Kidney Transplantation: Systematic Review and Meta-Analysis of Randomized Controlled Trials.Semantic proximity Read ↗

CYP3A5 genotyping-guided dosing versus weight-based dosing in a multi-ethnic population of kidney transplant recipientsSemantic proximity Read ↗

Recipient Versus Donor CYP3A4/5 Genotypes in Adult Liver Transplant Recipients to Achieve Therapeutic Tacrolimus Concentrations Early Post-Transplant.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing.Semantic proximity Read ↗

Population pharmacokinetics of tacrolimus in adult kidney transplant patients: impact of CYP3A5 genotype on starting dose.Semantic proximity Read ↗

Tacrolimus pharmacokinetics are influenced by CYP3A5, age, and concomitant fluconazole in pediatric kidney transplant patients.Semantic proximity Read ↗

The combination of CYP3A4*22 and CYP3A5*3 single-nucleotide polymorphisms determines tacrolimus dose requirement after kidney transplantation.Semantic proximity Read ↗

Effects of CYP3A4, CYP3A5, and ABCB1 genetic variants on tacrolimus metabolism during the early period after kidney transplantation.Semantic proximity Read ↗

Higher number of tacrolimus dose adjustments in kidney transplant recipients who are extensive and intermediate CYP3A5 metabolizers.Semantic proximity Read ↗

Precision Dosing for Tacrolimus Using Genotypes and Clinical Factors in Kidney Transplant Recipients of European Ancestry.Semantic proximity Read ↗

The Impact of CYP3A4*22 on Tacrolimus Pharmacokinetics and Outcome in Clinical Practice at a Single Kidney Transplant CenterSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.